2. Search Result
Search Result
Pathways Recommended: NF-κB
Results for "

mmp,NF-κB

" in MedChemExpress (MCE) Product Catalog:

960

Inhibitors & Agonists

8

Screening Libraries

3

Fluorescent Dye

10

Biochemical Assay Reagents

41

Peptides

4

MCE Kits

4

Inhibitory Antibodies

446

Natural
Products

56

Isotope-Labeled Compounds

4

Antibodies

1

Click Chemistry

12

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155998
    NF-κB-IN-11

    		NF-κB Inflammation/Immunology
    NF-κB-IN-11 (Compound 3i) is a NF-κB inhibitor. NF-κB-IN-11 inhibits TNF-α induced activation of NF-κB pathway, and inhibits nuclear translocation of NF-κB. NF-κB-IN-11 down-regulates the expression levels of phosphor-IKK, IκBα, and NF-κB p65. NF-κB-IN-11 has anti-inflammatory activity, and alleviates dextran sulfate sodium-induced colitis in mice. NF-κB-IN-11 (p.o.) shows a MTD more than 1852 mg/kg in mice acute toxicity assay .
    NF-κB-IN-11
  • HY-144765
    NF-κB-IN-4

    		NF-κB Apoptosis Neurological Disease Inflammation/Immunology
    NF-κB-IN-4 (compound 17) is a potent and BBB-penetrated NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .
    NF-κB-IN-4
  • HY-138537
    NF-κB-IN-1
    2 Publications Verification

    		 IKK Cancer
    NF-κB-IN-1, a 4-arylidene crucumin analogue, is a potent NF-κB signaling pathway inhibitor. NF-κB-IN-1 directly inhibits IKK to block NF-κB activation. NF-κB-IN-1 effectively inhibits the viability of lung cancer cells and attenuates the clonogenic activity of A549 cells .
    NF-κB-IN-1
  • HY-126026
    NF-κB-IN-17

    		NF-κB Inflammation/Immunology
    NF-κB-IN-17 (Zinc5) is a NF-κB inhibitor. NF-κB-IN-17 inhibits TNF-α-induced NF-κB DNA binding activity in C2C12 cells .
    NF-κB-IN-17
  • HY-149838
    NF-κB-IN-9

    		NF-κB Cancer
    NF-κB-IN-9 is a nuclear factor kappa B (NF-κB) targeting sonosensitizer (λex/λem=489/628 nm). NF-κB-IN-9 exhibits strong inhibition on NF-κB signaling due to its two resveratrol units in one molecule. NF-κB-IN-9 has anti-tumor activity and shows remarkable sonocytotoxicity against cancer cells. NF-κB-IN-9 has biosafety in eenograft mice model.
    NF-κB-IN-9
  • HY-144744
    NF-κB-IN-3

    		NF-κB Cancer
    NF-κB-IN-3 (Compound 2) is a NF-κB inhibitor with an IC50 of 0.70 µM. NF-κB-IN-3 can be used as an antitumor agent .
    NF-κB-IN-3
  • HY-162316
    NF-κB-IN-15

    		NF-κB Inflammation/Immunology
    NF-κB-IN-15 (compound 14r) is a potent NF-κB inhibitor. NF-κB-IN-15 decreases the NO levels and inhibits the release of IL-6, TNF-α, and IL-1β in LPS (HY-D1056) -induced cells. NF-κB-IN-15 inhibits LPS-induced phosphorylation of p65 and degradation of IκBα. NF-κB-IN-15 shows anti-inflammatory activity has the potential for the research of acute lung injury (ALI) .
    NF-κB-IN-15
  • HY-149580
    NF-κB-IN-12

    		NF-κB Inflammation/Immunology
    NF-κB-IN-12 (compound 3h) is a potent NF-κB inhibitor, with an IC50 of 1.02 μM. NF-κB-IN-12 can be used for acute lung injury research .
    NF-κB-IN-12
  • HY-149351
    NF-κB-IN-10

    		NF-κB Cardiovascular Disease
    NF-κB-IN-10 (compound E1) is an NF-κB inhibitor that can improve heart failure by reducing oxidative stress and inflammation by regulating Nrf2/NF-κB signaling pathway. NF-κB-IN-10 inhibits LPS-induced NO production and expression of iNOS and COX-2 in RAW264.7 cells. NF-κB-IN-10 can be used in the research of cardiovascular diseases .
    NF-κB-IN-10
  • HY-N12283
    NF-κB-IN-13

    		NF-κB Inflammation/Immunology
    NF-κB-IN-13 (compound 12) can significantly inhibit LPS-induced NF-κB activation and NO production in RAW264.7 macrophages. NF-κB-IN-13 has anti-inflammatory effects .
    NF-κB-IN-13
  • HY-149248
    NF-κB-IN-8

    		NF-κB Inflammation/Immunology
    NF-κB-IN-8 competitively antagonizes LPS binding to MD-2. NF-κB-IN-8 reduces the expression of inflammatory factors by binding to MD-2. NF-κB-IN-8 also inhibits ALP activity. NF-κB-IN-8 can be used for the research of inflammation such as acute lung injury (ALI) .
    NF-κB-IN-8
  • HY-142958
    NF-κB-IN-2

    		NF-κB Neurological Disease
    NF-κB-IN-2 inhibits TNF-α-induced canonical NF-κB signaling in PC-3 cells.
    NF-κB-IN-2
  • HY-162004
    NF-κB-IN-14

    		NF-κB Toll-like Receptor (TLR) Inflammation/Immunology
    NF-κB-IN-14 (compound 5e) significantly inhibits nitric oxide production in LPS-induced macrophages (IC50: 6.4 μM). NF-κB-IN-14 disrupts the TLR4-MyD88 protein interaction, leading to the suppression of the NF-κB signaling pathway suppression. NF-κB-IN-14 reduces ear edema and inflammation in an atopic dermatitis mouse model .
    NF-κB-IN-14
  • HY-158156
    NF-κB-IN-16

    		NF-κB Apoptosis Cancer
    NF-κB-IN-16 (compound 9) is a complex (Pt(IV) complex) of NF-κB inhibitor and Cisplatin (HY-17394), which has high efficacy and low toxicity in anti-tumor activity. active. NF-κB-IN-16 can cause DNA damage, induce mitochondrial dysfunction, produce reactive oxygen species, and induce apoptosis through the mitochondrial pathway and endoplasmic reticulum stress. NF-κB-IN-16 potently inhibits the NF-κB/MAPK signaling pathway and disrupts PI3K/AKT signaling. NF-κB-IN-16 also exhibits excellent in vivo antitumor efficiency and low toxicity in A549 or A549/CDDP xenograft models .
    NF-κB-IN-16
  • HY-147972
    NF-κB/MAPK-IN-1

    		NF-κB p38 MAPK NO Synthase COX Inflammation/Immunology
    NF-κB/MAPK-IN-1 (compound 11a) is a potent inhibitor of NF-κB and MAPK pathway. NF-κB/MAPK-IN-1 shows inhibitory activity against NO production, with an IC50 of 6.96 µM. NF-κB/MAPK-IN-1 suppresses LPS-induced iNOS, COX-2, ERΚ and P38 signaling activation. NF-κB/MAPK-IN-1 can prevent LPS induced inflammatory response in macrophages. NF-κB/MAPK-IN-1 can be used for rheumatoid arthritis (RA) research .
    NF-κB/MAPK-IN-1
  • HY-147682
    NF-κB-IN-5

    		NF-κB Apoptosis Cancer
    NF-κB-IN-5 (compound 4d) is an orally active and potent NF-κB inhibitor by interacting directly with NF-κB. NF-κB-IN-5 shows antitumor activity against human cancer cell lines (HCT116, U87-MG, HepG2, BGC823, PC9), with IC50 values of 5.35, 2.81, 2.83, 2.02 and 3.90 μM, respectively. NF-κB-IN-5 induces apoptosis in U87-MG tumor cell and cell cycle arrest in G0/G1 phase .
    NF-κB-IN-5
  • HY-147770
    NF-κB-IN-6

    		NF-κB Inflammation/Immunology
    NF-κB-IN-6 (Compound 3d) is an anti-inflammatory agent through the mechanism of decreasing the protein expressions of iNOS and COX-2 by suppressing NF-κB signaling pathway. NF-κB-IN-6 inhibits NO production in LPS-induced RAW264.7 cells with an IC50 of 23.1 μM .
    NF-κB-IN-6
  • HY-147836
    Akt/NF-κB/JNK-IN-1

    		Akt NF-κB JNK TNF Receptor COX Inflammation/Immunology
    Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, NF-κB and JNK signaling pathways. Akt/NF-κB/JNK-IN-1 inhibits nitric oxide production with an IC50 of 3.15 μM. Akt/NF-κB/JNK-IN-1 shows anti-inflammatory activities .
    Akt/NF-κB/JNK-IN-1
  • HY-161520
    Glucocorticoid receptor/NF-κB modulator-1

    		Glucocorticoid Receptor NF-κB Inflammation/Immunology
    Glucocorticoid receptor/NF-κB modulator-1 (Compound 20) is a derivative of ocotillol. Glucocorticoid receptor/NF-κB modulator-1 suppresses the degradation of glucocorticoid receptor (GR) mRNA and GR protein, inhibits the activation of NF-κB signaling pathway. Glucocorticoid receptor/NF-κB modulator-1 downregulates levels of NO, interleukin-6 and tumor necrosis factor-alpha (TNF-α). Glucocorticoid receptor/NF-κB modulator-1 ameliorates sepsis in mouse model .
    Glucocorticoid receptor/NF-κB modulator-1
  • HY-146058
    NF-κB/PON1-IN-1

    		NF-κB Reactive Oxygen Species Cancer
    NF-κB/PON1-IN-1 (Compound 16) is a NF-κB/PON1 pathway inhibitor. NF-κB/PON1-IN-1 has antioxidant (IC50 = 45.76 µM) and hepatoprotective activities .
    NF-κB/PON1-IN-1
  • HY-149496
    Akt/NF-κB/MAPK-IN-1

    		p38 MAPK ERK JNK Interleukin Related TNF Receptor NO Synthase COX Others
    Akt/NF-κB/MAPK-IN-1 (compound 2m) is a potent and orally active inhibitor against NO (IC50=7.70 μM) with no significant toxicity. Akt/NF-κB/MAPK-IN-1 shows anti-inflammatory activity by inhibiting Akt/NF-κB and MAPK signaling pathways .
    Akt/NF-κB/MAPK-IN-1
  • HY-142963
    TLR4/NF-κB/MAPK-IN-1

    		NF-κB p38 MAPK Toll-like Receptor (TLR) Neurological Disease Inflammation/Immunology
    TLR4/NF-κB/MAPK-IN-1 is a new type of antineuroinflammatory agent by suppressing TLR4/NF-kB/MAPK pathways.
    TLR4/NF-κB/MAPK-IN-1
  • HY-133987
    AP-1/NF-κB activation inhibitor 1
    1 Publications Verification

    		 NF-κB Inflammation/Immunology
    AP-1/NF-κB activation inhibitor 1 is a potent AP-1 and NF-κB mediated transcriptional activation inhibitor (IC50=1 μM), without blocking basal transcription driven by the β-actin promoter. AP-1/NF-κB activation inhibitor 1 has a similar inhibitory effect on the production of IL-2 and IL-8 levels in stimulated cells .
    AP-1/NF-κB activation inhibitor 1
  • HY-131385
    KB02-COOH

    		Ligands for E3 Ligase Cancer
    KB02-COOH is a fragment of synthesis of ubiquitin E3 ligase ligand KB02. KB02 can be used in the synthesis of PROTAC, such as KB02-JQ1 (HY-129917) and KB02-SLF (HY-129610) .
    KB02-COOH
  • HY-129610
    KB02-SLF

    		PROTACs FKBP Cancer
    KB02-SLF is a PROTAC-based nuclear FKBP12 degrader (molecular glue). KB02-SLF promotes nuclear FKBP12 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. SLF binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-SLF .
    KB02-SLF
  • HY-137478A
    KB-0742 dihydrochloride

    		CDK Cancer
    KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity .
    KB-0742 dihydrochloride
  • HY-137478
    KB-0742

    		CDK Cancer
    KB-0742 is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 has potent anti-tumor activity .
    KB-0742
  • HY-136741
    BOT-64
    1 Publications Verification

    		 IKK Inflammation/Immunology
    BOT-64 is an inhibitory κB (IκB) kinase β (IKKβ) inhibitor with an IC50 of 1 µM. BOT-64 blocks lipopolysaccharide-induced nuclear factor-κB activation and nuclear factor-κB-regulated inflammatory gene transcription .
    BOT-64
  • HY-19081
    KB-5246

    		Bacterial Antibiotic Infection
    KB-5246 is a tetracyclic quinolone and displays antibacterial activities.
    KB-5246
  • HY-10257
    BAY 11-7085
    30+ Cited Publications

    BAY 11-7083

    		 NF-κB Ferroptosis Apoptosis Cancer
    BAY 11-7085 (BAY 11-7083) is an inhibitor of NF-κB activation and phosphorylation of IκBα; it stabilizes IκBα with an IC50 of 10 μM .
    BAY 11-7085
  • HY-129917
    KB02-JQ1
    3 Publications Verification

    		 PROTACs Epigenetic Reader Domain Cancer
    KB02-JQ1 is a highly selective and PROTAC-based BRD4 degrader (molecular glue), but does not degrade BRD2 or BRD3. KB02-JQ1 promotes BRD4 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. JQ1 binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-JQ1 .
    KB02-JQ1
  • HY-13982
    JSH-23
    85+ Cited Publications

    		 NF-κB Metabolic Disease Inflammation/Immunology Cancer
    JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation .
    JSH-23
  • HY-N0277
    Aconine
    2 Publications Verification

    Jesaconine

    		 NF-κB Inflammation/Immunology Cancer
    Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced NF-κB activation.
    Aconine
  • HY-19498
    WAY-204688

    SIM-688

    		 NF-κB Inflammation/Immunology
    WAY-204688 is an estrogen receptor (ER-α) selective, orally active inhibitor of NF-κB transcriptional activity with an IC50 of 122 ± 30 nM for NF-κB-luciferase (NF-κB-luc) in HAECT-1 cells.
    WAY-204688
  • HY-162092
    Multi-target Pt

    		NF-κB IKK Cancer
    Multi-target Pt (IV), an antitumor agent, suppresses the IKKβ phosphorylation, IκBα phosphorylation and NF-κB p65 phosphorylation and nuclear translocation, leading to blocked the NF-kB signal pathway .
    Multi-target Pt
  • HY-120026
    KB130015

    KB015

    		 Thyroid Hormone Receptor Neurological Disease
    KB130015 (KB015) is an orally active and potent ThRα and ThRβ (Thyroid Hormone Receptor) inhibitor, with IC50 values of 4.5 and 5.1 μM, respectively. KB130015 has antiarrhythmic properties. KB130015 markedly slows the kinetics of inactivation of Na + channels. KB130015 opens large-conductance Ca 2+-activated K + channels and relaxes vascular smooth muscle .
    KB130015
  • HY-107593
    PS-1145 dihydrochloride

    		IKK Inflammation/Immunology
    PS-1145 (dihydrochloride) is a potent IκB kinase-2 inhibitor with an IC50 value of 88 nM. PS-1145 (dihydrochloride) inhibits activity of NF-κB by blocking IκB kinase phosphorylation in tumor-bearing rats .
    PS-1145 dihydrochloride
  • HY-19120
    KB-5492 anhydrous

    		Sigma Receptor Inflammation/Immunology
    KB-5492 anhydrous is a potent and selective inhibitor of sigma receptor, inhibits specific [ 3H]1,3-di(2-tolyl)guanidine (DTG) binding to the sigma receptor with an IC50 of 3.15 μM. KB-5492 anhydrous is an anti-ulcer agent .
    KB-5492 anhydrous
  • HY-138284
    Avenanthramide-C methyl ester

    		NF-κB Inflammation/Immunology
    Avenanthramide-C methyl ester is an anti-inflammatory agent and NF-κB inhibitor that inhibits the secretion of pro-inflammatory factors. Avenanthramide-C methyl ester inhibits NF-κB activation by inhibiting IKK and IκB phosphorylation and inhibiting proteasome activity .
    Avenanthramide-C methyl ester
  • HY-47228
    KB-5492 free base

    		Sigma Receptor Inflammation/Immunology
    KB-5492 free base is a potent and selective inhibitor of sigma receptor, inhibits specific [ 3H]1,3-di(2-tolyl)guanidine (DTG) binding to the sigma receptor with an IC50 of 3.15 μM. KB-5492 free base is an anti-ulcer agent .
    KB-5492 free base
  • HY-N0694
    Schisantherin A
    1 Publications Verification

    Gomisin-C; Schizantherin-A; Wuweizi ester-A

    		 NF-κB Inflammation/Immunology
    Schisantherin A is a dibenzocyclooctadiene lignan. Schisantherin A inhibits p65-NF-κB translocation into the nucleus by IκBα degradation.
    Schisantherin A
  • HY-149461
    KB-05

    		Others Others
    KB-05 is an electrophilic fragment molecule that can be used in DIA-based quantitative chemical proteomic screening studies.
    KB-05
  • HY-N1987
    Cucurbitacin IIb
    1 Publications Verification

    		 Apoptosis Inflammation/Immunology
    Cucurbitacin IIb is an active component isolated from Hemsleya amabilis, induces apoptosis with anti-inflammatory activity. Cucurbitacin IIb inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB (p65), blocks nuclear translocation of NF-κB (p65) and decreases mRNA levels of IκBα and TNF-α .
    Cucurbitacin IIb
  • HY-144745
    HSR1304

    		NF-κB Cancer
    HSR1304 (Compound 5d) is a potent inhibitor of NFκB. The multifunctional transcription factor, nuclear factor-κB (NF-κB), is broadly involved in multiple human diseases, such as cancer and chronic inflammation. HSR1304 has the potential for the research of cancer diseases .
    HSR1304
  • HY-P1832A
    PTD-p65-P1 Peptide TFA
    3 Publications Verification

    		 NF-κB Apoptosis Inflammation/Immunology Cancer
    PTD-p65-P1 Peptide TFA is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis .
    PTD-p65-P1 Peptide TFA
  • HY-P1832
    PTD-p65-P1 Peptide

    		NF-κB Apoptosis Inflammation/Immunology Cancer
    PTD-p65-P1 Peptide is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis .
    PTD-p65-P1 Peptide
  • HY-117167
    KB-141

    		Thyroid Hormone Receptor Cancer
    KB-141 is a potent and selective TRβ agonist. The IC50 values are 23.9 nM and 3.3 nM for binding affinities from displacement of T3 from hTRα1 and hTRβ1, respectively. KB-141 has anti-obesity, anti-diabetic, and lipid-lowering effects?and can be used as an anti-cholesteremic agent in vivo .
    KB-141
  • HY-124651
    SEMBL

    		NF-κB MMP Inflammation/Immunology Cancer
    SEMBL is a potent NF-κB inhibitor. SEMBL can inhibit NF-κB-DNA binding, and also inhibits NF-κB-dependent inflammatory cytokine secretions. SEMBL inhibits cancer cell migration and invasion via decreasing MMP expression. SEMBL can be used for researching anticancer .
    SEMBL
  • HY-N0191
    Andrographolide
    15+ Cited Publications

    Andrographis

    		 NF-κB SARS-CoV Influenza Virus Autophagy Parasite Infection Inflammation/Immunology Cancer
    Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.
    Andrographolide
  • HY-136208
    TAN-452

    		Opioid Receptor Neurological Disease
    TAN-452 is an orally active, selective peripherally acting δ-opioid receptor (DOR) antagonist with a Ki of 0.47 nM and a Kb of 0.21 nM. TAN-452 is an antagonist for μ-opioid receptor (MOR; Ki=36.56 nM and Kb=9.43 nM) and κ-opioid receptor (KOR; Ki=5.31 nM and Kb=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control .
    TAN-452

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: